Adverse events
cholecystitis, gastro-intestinal symptom-related, vomiting
ADVERSE EVENTS, ADVERSE EVENT, CHOLECYSTITIS
Forty-two adverse events (AE) occurred during the trial: 32 were in the liraglutide arm, and 10 were in the placebo arm. There were three serious adverse events (SAEs) during the trial: 2 in the liraglutide arm and 1 in the placebo arm. The most serious occurred in the placebo arm: cholecystitis requiring cholecystectomy. Investigational medicinal product was stopped for 5 participants in the liraglutide arm due to adverse events (5/13). Twenty-seven gastro-intestinal symptom-related AEs occurred: 20 in the liraglutide arm and 7 in the placebo arm. Gastric Band-related side effects also occurred more commonly in the liraglutide arm (L: 15 band-related AEs, P: 5 band-related AEs). 7 adverse events were ongoing at the end of the study, all in the liraglutide arm. Gastrointestinal side-effects occurred more frequently in the liraglutide arm, the most frequent being vomiting (Adverse events.Average number of adverse events (AEs) per patient as well as average time to AE and duration of AE across patients is reported as median (interquartile range). The number of patients with surgery-related and gastric band-related AEs is reported as 